BR0100558A - Composições e métodos para tratar a osteoporose - Google Patents

Composições e métodos para tratar a osteoporose

Info

Publication number
BR0100558A
BR0100558A BR0100558-8A BR0100558A BR0100558A BR 0100558 A BR0100558 A BR 0100558A BR 0100558 A BR0100558 A BR 0100558A BR 0100558 A BR0100558 A BR 0100558A
Authority
BR
Brazil
Prior art keywords
methods
compositions
treating osteoporosis
active ingredient
carrier
Prior art date
Application number
BR0100558-8A
Other languages
English (en)
Inventor
Wesley Warren Day
Andrew George Lee
David Duane Thompson
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR0100558A publication Critical patent/BR0100558A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Patente de Invenção: <B>"COMPOSIçõES E MéTODOS PARA TRATAR A OSTEOPOROSE"<D>. A presente invenção refere-se a métodos, composições farmacêuticas e kits úteis para a promoção da formação de massa óssea e/ou a prevenção da perda da mesma e/ou o tratamento da aterosclerose. As composições incluem um polifosfonato como primeiro ingrediente ativo e uma estatina como segundo ingrediente ativo, além de um veículo, carreador ou diluente farmaceuticamente aceitável.
BR0100558-8A 2000-02-15 2001-02-15 Composições e métodos para tratar a osteoporose BR0100558A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18271300P 2000-02-15 2000-02-15

Publications (1)

Publication Number Publication Date
BR0100558A true BR0100558A (pt) 2001-09-11

Family

ID=22669683

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0100558-8A BR0100558A (pt) 2000-02-15 2001-02-15 Composições e métodos para tratar a osteoporose

Country Status (5)

Country Link
US (1) US20010036936A1 (pt)
EP (1) EP1127573A1 (pt)
JP (1) JP2001253827A (pt)
BR (1) BR0100558A (pt)
CA (1) CA2337381A1 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2372450A1 (en) * 2001-05-10 2001-09-19 Pharmaceutical Partners Of Canada Inc. Liquid injectable formulation of disodium pamidronate
JP2002370982A (ja) * 2001-06-12 2002-12-24 Kowa Co 骨形成促進剤
US20050070504A1 (en) * 2001-12-21 2005-03-31 The Procter & Gamble Co. Risedronate compositions and their methods of use
US7208481B2 (en) 2002-02-19 2007-04-24 Ilex Products, Inc. Aminodiphosphonate apolipoprotein E modulators
DK1490024T3 (da) 2002-03-06 2012-04-10 Effrx Pharmaceuticals Sa Alendronatholdige brusesammensætninger
US7488496B2 (en) 2002-03-06 2009-02-10 Christer Rosen Effervescent compositions comprising bisphosphonates and methods related thereto
KR20030075715A (ko) * 2002-03-20 2003-09-26 학교법인 경희대학교 성장촉진활성을 갖는 로바스타틴, 이를 포함하는 약제학적조성물 및 이의 사용방법
BR0308901A (pt) * 2002-05-10 2005-01-04 Hoffmann La Roche ácidos bisfosfÈnicos para tratamento e prevenção de osteoporose
US20040043072A1 (en) * 2002-09-04 2004-03-04 Will Joanne Patricia Alleviation of upper gastrointestinal irritation
US20060166937A1 (en) * 2002-10-15 2006-07-27 Prescott Margaret F Bisphosphonates for the treatment of atherosclerosis and device comprising them
GB0327742D0 (en) * 2003-11-28 2003-12-31 Isis Innovation Novel uses of known drugs
US8202546B2 (en) 2005-08-04 2012-06-19 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
US7998500B2 (en) 2005-08-04 2011-08-16 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
US8263137B2 (en) 2005-08-04 2012-09-11 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
US7901710B2 (en) 2005-08-04 2011-03-08 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
US20080176787A1 (en) * 2005-09-06 2008-07-24 Paul Morley Parathyroid hormone analogues and methods of use
US20110046059A1 (en) * 2005-09-06 2011-02-24 Zelos Therapeutics, Inc. Pharmaceutically acceptable formulations/compositions for peptidyl drugs
ITMI20052515A1 (it) * 2005-12-29 2007-06-30 Abiogen Pharma Spa Formulazione farmaceutica per il trattamento della osteoartrite
EP1996118A4 (en) * 2006-03-07 2013-03-06 Osteoscreen Ip Llc STRENGTHENING BONES AND CARTILES BY HMG-CO-A REDUCTASE INHIBITOR
FR2903312B1 (fr) * 2006-07-05 2008-09-26 Univ Aix Marseille Ii Utilisation d'inhibiteurs d'hmg-coa reductase et de farnesyl-pyrophosphate synthase dans la preparation d'un medicament
WO2008059060A1 (en) * 2006-11-17 2008-05-22 Besins Healthcare Liquid pharmaceutical compositions comprising a bisphosphonate compound
AU2008353145B2 (en) * 2008-01-03 2013-09-12 Universite D' Aix-Marseille Bitherapy and tritherapy used for treating an HIV-positive patient
FR2926020B1 (fr) * 2008-01-03 2010-08-13 Univ Aix Marseille Ii Composition cosmetique et/ou dermatologique
WO2010014184A1 (en) * 2008-07-28 2010-02-04 Svip1 Llc Parenteral treatment with statins
US20110293740A1 (en) * 2010-05-26 2011-12-01 Baucom Karan Y Treatment system and method for osteopenia and osteoporosis using non-synthetic bio-available compounds
EP2749285B1 (en) 2011-08-26 2016-11-02 National University Corporation Nagoya University Osteogenesis promoter and use thereof
US8802658B2 (en) 2012-05-14 2014-08-12 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating disease
WO2014039541A1 (en) * 2012-09-05 2014-03-13 North American Salt Company Methods and compositions to prevent caking of sodium chloride and prevent transition metal stains

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3473193A (en) * 1992-01-17 1993-08-03 Procter & Gamble Company, The Treatment for atherosclerosis
JP2002506030A (ja) * 1998-03-13 2002-02-26 メルク エンド カムパニー インコーポレーテッド 骨再吸収の阻害方法

Also Published As

Publication number Publication date
EP1127573A1 (en) 2001-08-29
CA2337381A1 (en) 2001-08-15
JP2001253827A (ja) 2001-09-18
US20010036936A1 (en) 2001-11-01

Similar Documents

Publication Publication Date Title
ATE500218T1 (de) Mittel zur behandlung von erkrankungen, die mit knochenschwund einhergehen, mit ep4-agonist als wirkstoff
BR0308901A (pt) ácidos bisfosfÈnicos para tratamento e prevenção de osteoporose
BR0211888A (pt) Materiais e métodos para promoção de reparo de tecido nervoso
BRPI0408681A (pt) compostos, composições farmacêuticas, uso de um derivado da 1,2,3,4-tetraidroisoquinolina, método para tratar ou prevenir doenças, processo para a manufatura de composições farmacêuticas, e, uso de um ou mais compostos
MXPA02005173A (es) Composicion farmaceutica para el tratamiento de enfermedades asociadas con disminucion de masa osea.
SE9803710D0 (sv) Use of certain drugs for treating nerve root injury
ZA9711607B (en) Novel cyclosporin derivatives, their preparation and the pharmaceutical compositions which contain them.
BR0309875A (pt) métodos e composições para tratamento de distúrbios do sistema nervoso periférico e novos compostos úteis para isto
SE9901272D0 (sv) New improved formulation
BR0207760A (pt) Composição farmacêutica, uso da mesma, métodos para o tratamento de dor e de inflamação, e, processo para a preparação de uma composição
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
BR0014384A (pt) Compostos para o tratamento da isquémia
CY1109661T1 (el) 5-cnac ως παραγοντας για χορηγηση απο το στομα τμηματων παραθορμονης
BR0000003A (pt) Azalidas e métodos de preparação das mesmas
BR0210122A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo
BRPI0507628A (pt) composto ou sal farmaceuticamente aceitável do mesmo, método de tratamento de uma infecção viral em um ser humano, uso de um composto composição farmacêutica, e, processo para a preparação de um composto
BR0105457A (pt) Combinações terapêuticas para estimulação do crescimento ósseo
BR9708114A (pt) Análogos xantona para o tratamento de doenças infecciosas.
BR0207978A (pt) N-but-3enil norbuprenorfina e métodos de uso
PT1001792E (pt) Utilizacao de compostos de sais e de complexos de vanadio aceites fisiologicamente
BR0115424A (pt) Composto, composição farmacêutica, métodos para inibir a liberação de peptìdeo beta-amilóide e/ou sua sìntese, para tratar a doença de alzheimer, para prevenir a doença de alzheimer, e para inibir o progresso da doença de alzheimer, processos para preparar o composto, e para preparar lactamas, e, uso do composto
WO2004067027A3 (en) Osteogenic composition
EP1262197A3 (en) Combination treatment for sleep disorders including sleep apnea
MXPA02011921A (es) Inhibidores de dipeptidasa acida n-acetilada-alfa-enlazada para el tratamiento de trastornos retinianos y glaucona.
RU2001124802A (ru) Применение саредутанта и его фармацевтически приемлемых солей для приготовления лекарственных средств, применяемых для лечения или предупреждения расстройств настроения, расстройств адаптации или смешанных тревожно-депрессивных расстройств

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1962 DE 12/08/2008.